Therapy Areas: Diabetes
Sunvera Group Forms New Partnership with William S. Goldstein, MD PC Laser Eye Care Center
18 May 2022 - - US-based management services organization Sunvera Group, which provides support services to ophthalmology practices across multiple subspecialties, has formed a new partnership with Wi...
Vraniak Named Chief Financial Officer at Inversago Pharma
18 May 2022 - - Canadian clinical stage biotechnology company Inversago Pharma Inc., which has a portfolio of CB1 inverse agonists, has appointed Glenn S. Vraniak to the position of chief financial of...
Vertex dedicates Jeffrey Leiden Center for Cell and Genetic Therapies and announces further Boston Seaport expansion
18 May 2022 - At a dedication of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston's Seaport on Tuesday US-based Vertex Pharmaceuticals Inc (Nasdaq: VRTX) announced plans to ...
UK Grants Licence for Teva's Ophthalmology Biosimilar Ongavia
17 May 2022 - - The UK Medicines and Healthcare Regulatory Agency decision to grant a licence for Ongavia, a biosimilar to Lucentis (ranibizumab), an eye injection, Israeli pharmaceutical co...
First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
17 May 2022 - - The first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors, ...
Eli Lilly to Participate in UBS Global Healthcare Conference 2022
17 May 2022 - US-based pharmaceutical company Eli Lilly and Company (NYSE: LLY) announced on Monday that it will attend the UBS Global Healthcare Conference on Tuesday, 24 May 2022.Michael Mason, seni...
Related Headlines

Glyscend Therapeutics Completes Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

Bradrick Named to Spectrum Pharmaceuticals Board of Directors

AstraZeneca's Farxiga Met Primary Endpoint in DELIVER Phase III trial, Reducing Risk of Cardiovascular Death

Oramed Pharmaceuticals completes patient enrolment for Phase 3 ORA-D-013-1 study of ORMD-0801

Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF1, in Partnership with Nestlé Health Science

First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine Using Proprietary B-Tech Vector Platform

Former ViaCyte CEO Paul Laikind Joins Stemson Therapeutics Board of Directors

Diamyd Medical AB announces clinical trial of Diamyd booster in diabetes patients

Sciwind Biosciences start dosing subjects in phase one XW004 clinical trial

Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy

Aptinyx Reports Disappointing Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

LimFlow Raises USD 40m in Series D Financing

Löhr Named to PharmaCyte Biotech Board of Directors

Bond Biosciences Doses First Sentinel Patients in a Phase Ia/b Clinical Trial for a Novel Therapy to Treat Patients with Hemochromatosis